Pharmacogenomics — MCQs

Q: Testing of HLA-B' 5701 is recommended prior to initiation of which antiretroviral agent?

Abacavir. The correct answer is **Abacavir (Option D)**. **1. Why Abacavir is Correct:** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)** [1]. This reaction is strongly linked to the presence of the **HLA-B*57:01** allele. In individuals carrying this allele, abacavir binds to the HLA-B*57:01 protein, altering the shape of the antigen-binding cleft [1]. This causes the immune system to recognize self-peptides as foreign, triggering a massive T-cell response. Screening for this allele is now a standard of care; if a patient tests positive, abacavir is strictly contraindicated [1]. **2. Why Other Options are Incorrect:** * **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) by inhibiting the UGT1A1 enzyme, but it is not linked to HLA-B*57:01 [1]. * **Nelfinavir (B):** An older PI primarily associated with gastrointestinal side effects (diarrhea). No specific HLA screening is required. * **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can rarely cause Stevens-Johnson Syndrome (SJS), there is no routine pharmacogenetic screening recommended prior to its use. **3. High-Yield Clinical Pearls for NEET-PG:** * **Abacavir HSR Symptoms:** Fever, rash, GI distress, and respiratory symptoms. **Re-challenge** after a suspected reaction is **fatal**. * **Other High-Yield HLA Associations:** * **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (specifically in Asian populations). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR). * **Mnemonic:** "A-B-C" — **A**bacavir **B**inds **C**left of HLA-B*57:01.

Q: Which HLA gene is associated with abacavir hypersensitivity?

B57. **Explanation:** **Correct Option: D (HLA-B*57:01)** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV treatment. Approximately 5–8% of patients develop a potentially fatal **Abacavir Hypersensitivity Syndrome (AHS)**, characterized by fever, rash, and gastrointestinal symptoms. This reaction is strongly associated with the **HLA-B*57:01** allele. The drug binds to the antigen-binding cleft of this specific HLA molecule, altering the repertoire of self-peptides presented to T-cells, which triggers an autoimmune-like systemic inflammatory response. Screening for this allele is mandatory before initiating abacavir to prevent AHS. **Incorrect Options:** * **A (B5):** This is a broad serotype that includes B51 and B52 but is not specifically linked to abacavir. * **B (B51):** This allele is the classic genetic marker associated with **Behçet’s Disease** (characterized by oral/genital ulcers and uveitis). * **C (DQ2):** This is an HLA Class II allele strongly associated with **Celiac Disease** (along with HLA-DQ8). **High-Yield Clinical Pearls for NEET-PG:** 1. **Mandatory Screening:** If a patient tests positive for HLA-B*57:01, Abacavir is strictly **contraindicated** and should be listed as an allergy in their records. 2. **Re-challenge Warning:** Never re-challenge a patient with abacavir if AHS is suspected; it can lead to rapid, fatal hypotension and multi-organ failure. 3. **Other HLA-Drug Associations:** * **HLA-B*15:02:** Carbamazepine-induced Stevens-Johnson Syndrome (SJS) (especially in Asians). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR).

Q: All of the following drugs cause hemolysis in G-6PD deficiency except?

Erythromycin. ### Explanation **Concept Overview:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the supply of **reduced glutathione**. This molecule protects red blood cells (RBCs) from oxidative stress. In G6PD deficiency, exposure to oxidizing agents leads to the denaturation of hemoglobin (forming **Heinz bodies**) and subsequent hemolysis. **Why Erythromycin is the Correct Answer:** **Erythromycin** is a macrolide antibiotic that does not possess significant oxidizing properties. It is considered safe to use in patients with G6PD deficiency. It does not interfere with the redox state of the erythrocyte or trigger the destruction of RBCs. **Analysis of Incorrect Options:** * **Primaquine:** This is the classic "textbook" trigger. It is an antimalarial that generates reactive oxygen species (ROS), causing severe hemolysis in G6PD-deficient individuals. * **Nitrofurantoin:** A urinary antiseptic known to cause oxidative stress. It is strictly contraindicated in G6PD-deficient patients due to the high risk of hemolytic anemia. * **Sulfonamides (e.g., Sulfamethoxazole):** These drugs act as oxidizing agents. They are well-documented triggers for hemolytic crises in affected patients. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder (more common in males). * **Peripheral Smear Findings:** Look for **Heinz bodies** (denatured hemoglobin) and **Bite cells** (degmacytes) formed by splenic macrophages removing these bodies. * **Other Common Triggers:** Dapsone, Rasburicase, Methylene blue, and **Fava beans** (Favism). * **Safe Alternatives:** Penicillins, Cephalosporins, and Macrolides (like Erythromycin) are generally safe. * **Key Contraindication:** Never give **Primaquine** without first screening the patient for G6PD levels.

Q: Therapeutic drug monitoring is used in which of the following medications?

Digoxin. **Explanation:** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is primarily indicated for drugs with a **narrow therapeutic index**, where the difference between the effective dose and the toxic dose is minimal. **Why Digoxin is the Correct Answer:** Digoxin has a very narrow therapeutic index (typically **0.5–2.0 ng/mL**). Small fluctuations in serum levels can lead to life-threatening toxicity (arrhythmias, xanthopsia, or gastrointestinal distress). Factors like renal impairment, hypokalemia, and drug interactions (e.g., with Amiodarone or Verapamil) significantly alter its pharmacokinetics, making TDM essential for safety and efficacy. **Why Other Options are Incorrect:** * **A. Diuretics:** Their effect is easily monitored clinically by measuring urine output, body weight, blood pressure, and serum electrolytes. * **B. Metformin:** Its efficacy is monitored by measuring clinical markers like blood glucose levels and HbA1c, rather than plasma drug concentrations. * **C. Levodopa:** The clinical response (improvement in Parkinsonian symptoms) and the appearance of side effects (dyskinesia) are used to titrate the dose. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Remember the mnemonic **"THEAL"** – **T**ricyclic antidepressants, **H**eart meds (Digoxin, Quinidine), **E**pilepsy meds (Phenytoin, Carbamazepine), **A**minoglycosides (Gentamicin), and **L**ithium. * **Sampling Time:** For Digoxin, TDM should be performed at least **6–8 hours after the last dose** (post-distribution phase) to ensure accurate results. * **Exceptions:** TDM is **not** useful for drugs with "hit and run" pharmacokinetics (e.g., Omeprazole) or those with easily measurable physiological endpoints (e.g., Warfarin via PT/INR).

Q: Which of the following is an ionotropic receptor?

Nicotinic cholinergic receptor. **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Q: HLA* 1502 is a genetic marker associated with which of the following conditions?

Stevens-Johnson Syndrome. ### Explanation **Correct Answer: C. Stevens-Johnson Syndrome** The **HLA-B*1502** allele is a critical pharmacogenetic marker strongly associated with an increased risk of **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)** in patients treated with **Carbamazepine**. This association is particularly prevalent in populations of **East Asian and Southeast Asian** descent (e.g., Han Chinese, Thai, Indians). The mechanism involves a T-cell mediated hypersensitivity reaction where the drug (Carbamazepine) binds to the HLA-B*1502 molecule, triggering an immune response against keratinocytes. Due to this high correlation, the FDA recommends screening for this allele in high-risk populations before initiating Carbamazepine therapy. **Analysis of Incorrect Options:** * **A. Systemic Lupus Erythematosus (SLE):** Associated primarily with **HLA-DR2** and **HLA-DR3**. Drug-induced SLE is linked to "slow acetylators" (NAT2 deficiency) taking drugs like Procainamide or Hydralazine. * **B. Polyarteritis Nodosa:** Strongly associated with **Hepatitis B surface antigen (HBsAg)** positivity, not a specific HLA-B allele. * **D. Seronegative Spondyloarthritis:** This group of disorders (including Ankylosing Spondylitis) is classically associated with **HLA-B27**. **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*5701:** Associated with hypersensitivity to **Abacavir** (NRTI). * **HLA-B*5801:** Associated with SJS/TEN induced by **Allopurinol** (especially in Han Chinese). * **HLA-A*3101:** Another marker for Carbamazepine-induced skin reactions, more common in Europeans and Japanese. * **Drug of choice for SJS/TEN:** Supportive care and IV Immunoglobulins (IVIG). Cyclosporine is also used.

Q: Which of the following drugs is hydrolyzed by a plasma esterase that has abnormally low activity in about 1 in every 2500 humans?

Succinylcholine. **Explanation:** **1. Correct Option: Succinylcholine** Succinylcholine is a depolarizing neuromuscular blocker used for rapid sequence induction. Its action is normally terminated within 5–10 minutes because it is rapidly hydrolyzed by **Butyrylcholinesterase (BChE)**, also known as **Pseudocholinesterase** or **Plasma Cholinesterase**. About 1 in 2500 individuals (of European descent) carries an autosomal recessive trait for **atypical pseudocholinesterase**. In these patients, the enzyme has a low affinity for the drug, leading to a failure to hydrolyze succinylcholine. This results in prolonged neuromuscular blockade and life-threatening respiratory paralysis, a clinical condition known as **Succinylcholine Apnea**. **2. Incorrect Options:** * **Ethanol:** Primarily metabolized in the liver by Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH). While ALDH deficiency is common in Asian populations (causing "flushing"), it is not a plasma esterase. * **Rifampicin:** A potent inducer of Cytochrome P450 enzymes. It is metabolized via hepatic deacetylation, not plasma esterases. * **Cimetidine:** An H2 blocker and a well-known enzyme inhibitor. It is eliminated via a combination of hepatic metabolism and renal excretion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dibucaine Number:** This is the diagnostic test for atypical pseudocholinesterase. Dibucaine inhibits normal enzyme by 80%, but atypical enzyme by only 20%. A **low Dibucaine number** indicates a high risk for apnea. * **Management:** If apnea occurs, the patient must be maintained on **mechanical ventilation** until the drug wears off naturally. * **Mivacurium:** Another neuromuscular blocker also metabolized by pseudocholinesterase that can cause prolonged paralysis in these patients.

Pharmacogenomics Indian Medical PG Practice Questions and MCQs

Question 1: Testing of HLA-B' 5701 is recommended prior to initiation of which antiretroviral agent?

A. Atazanavir
B. Nelfinavir
C. Raltegravir
D. Abacavir (Correct Answer)

Explanation: The correct answer is **Abacavir (Option D)**. **1. Why Abacavir is Correct:** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)** [1]. This reaction is strongly linked to the presence of the **HLA-B*57:01** allele. In individuals carrying this allele, abacavir binds to the HLA-B*57:01 protein, altering the shape of the antigen-binding cleft [1]. This causes the immune system to recognize self-peptides as foreign, triggering a massive T-cell response. Screening for this allele is now a standard of care; if a patient tests positive, abacavir is strictly contraindicated [1]. **2. Why Other Options are Incorrect:** * **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) by inhibiting the UGT1A1 enzyme, but it is not linked to HLA-B*57:01 [1]. * **Nelfinavir (B):** An older PI primarily associated with gastrointestinal side effects (diarrhea). No specific HLA screening is required. * **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can rarely cause Stevens-Johnson Syndrome (SJS), there is no routine pharmacogenetic screening recommended prior to its use. **3. High-Yield Clinical Pearls for NEET-PG:** * **Abacavir HSR Symptoms:** Fever, rash, GI distress, and respiratory symptoms. **Re-challenge** after a suspected reaction is **fatal**. * **Other High-Yield HLA Associations:** * **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (specifically in Asian populations). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR). * **Mnemonic:** "A-B-C" — **A**bacavir **B**inds **C**left of HLA-B*57:01.

Question 2: Which HLA gene is associated with abacavir hypersensitivity?

A. B5
B. B51
C. DQ2
D. B57 (Correct Answer)

Explanation: **Explanation:** **Correct Option: D (HLA-B*57:01)** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV treatment. Approximately 5–8% of patients develop a potentially fatal **Abacavir Hypersensitivity Syndrome (AHS)**, characterized by fever, rash, and gastrointestinal symptoms. This reaction is strongly associated with the **HLA-B*57:01** allele. The drug binds to the antigen-binding cleft of this specific HLA molecule, altering the repertoire of self-peptides presented to T-cells, which triggers an autoimmune-like systemic inflammatory response. Screening for this allele is mandatory before initiating abacavir to prevent AHS. **Incorrect Options:** * **A (B5):** This is a broad serotype that includes B51 and B52 but is not specifically linked to abacavir. * **B (B51):** This allele is the classic genetic marker associated with **Behçet’s Disease** (characterized by oral/genital ulcers and uveitis). * **C (DQ2):** This is an HLA Class II allele strongly associated with **Celiac Disease** (along with HLA-DQ8). **High-Yield Clinical Pearls for NEET-PG:** 1. **Mandatory Screening:** If a patient tests positive for HLA-B*57:01, Abacavir is strictly **contraindicated** and should be listed as an allergy in their records. 2. **Re-challenge Warning:** Never re-challenge a patient with abacavir if AHS is suspected; it can lead to rapid, fatal hypotension and multi-organ failure. 3. **Other HLA-Drug Associations:** * **HLA-B*15:02:** Carbamazepine-induced Stevens-Johnson Syndrome (SJS) (especially in Asians). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR).

Question 3: All of the following drugs cause hemolysis in G-6PD deficiency except?

A. Primaquine
B. Nitrofurantoin
C. Sulfonamides
D. Erythromycin (Correct Answer)

Explanation: ### Explanation **Concept Overview:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the supply of **reduced glutathione**. This molecule protects red blood cells (RBCs) from oxidative stress. In G6PD deficiency, exposure to oxidizing agents leads to the denaturation of hemoglobin (forming **Heinz bodies**) and subsequent hemolysis. **Why Erythromycin is the Correct Answer:** **Erythromycin** is a macrolide antibiotic that does not possess significant oxidizing properties. It is considered safe to use in patients with G6PD deficiency. It does not interfere with the redox state of the erythrocyte or trigger the destruction of RBCs. **Analysis of Incorrect Options:** * **Primaquine:** This is the classic "textbook" trigger. It is an antimalarial that generates reactive oxygen species (ROS), causing severe hemolysis in G6PD-deficient individuals. * **Nitrofurantoin:** A urinary antiseptic known to cause oxidative stress. It is strictly contraindicated in G6PD-deficient patients due to the high risk of hemolytic anemia. * **Sulfonamides (e.g., Sulfamethoxazole):** These drugs act as oxidizing agents. They are well-documented triggers for hemolytic crises in affected patients. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder (more common in males). * **Peripheral Smear Findings:** Look for **Heinz bodies** (denatured hemoglobin) and **Bite cells** (degmacytes) formed by splenic macrophages removing these bodies. * **Other Common Triggers:** Dapsone, Rasburicase, Methylene blue, and **Fava beans** (Favism). * **Safe Alternatives:** Penicillins, Cephalosporins, and Macrolides (like Erythromycin) are generally safe. * **Key Contraindication:** Never give **Primaquine** without first screening the patient for G6PD levels.

Question 4: Therapeutic drug monitoring is used in which of the following medications?

A. Diuretic
B. Metformin
C. Levodopa
D. Digoxin (Correct Answer)

Explanation: **Explanation:** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is primarily indicated for drugs with a **narrow therapeutic index**, where the difference between the effective dose and the toxic dose is minimal. **Why Digoxin is the Correct Answer:** Digoxin has a very narrow therapeutic index (typically **0.5–2.0 ng/mL**). Small fluctuations in serum levels can lead to life-threatening toxicity (arrhythmias, xanthopsia, or gastrointestinal distress). Factors like renal impairment, hypokalemia, and drug interactions (e.g., with Amiodarone or Verapamil) significantly alter its pharmacokinetics, making TDM essential for safety and efficacy. **Why Other Options are Incorrect:** * **A. Diuretics:** Their effect is easily monitored clinically by measuring urine output, body weight, blood pressure, and serum electrolytes. * **B. Metformin:** Its efficacy is monitored by measuring clinical markers like blood glucose levels and HbA1c, rather than plasma drug concentrations. * **C. Levodopa:** The clinical response (improvement in Parkinsonian symptoms) and the appearance of side effects (dyskinesia) are used to titrate the dose. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Remember the mnemonic **"THEAL"** – **T**ricyclic antidepressants, **H**eart meds (Digoxin, Quinidine), **E**pilepsy meds (Phenytoin, Carbamazepine), **A**minoglycosides (Gentamicin), and **L**ithium. * **Sampling Time:** For Digoxin, TDM should be performed at least **6–8 hours after the last dose** (post-distribution phase) to ensure accurate results. * **Exceptions:** TDM is **not** useful for drugs with "hit and run" pharmacokinetics (e.g., Omeprazole) or those with easily measurable physiological endpoints (e.g., Warfarin via PT/INR).

Question 5: Which of the following is an ionotropic receptor?

A. Muscarinic cholinergic receptor
B. Nicotinic cholinergic receptor (Correct Answer)
C. Glucocorticoid receptor
D. Insulin receptor

Explanation: **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Question 6: Which of the following drugs does not act on cytoplasmic receptors?

A. Corticosteroids
B. Vitamin D
C. Aldosterone
D. Thyroxine (Correct Answer)

Explanation: **Explanation:** The mechanism of action of hormones depends on their lipid solubility and the location of their specific receptors. Receptors for lipid-soluble ligands are classified as **Intracellular Receptors**, which are further divided into **Cytoplasmic** and **Nuclear** types. **Why Thyroxine is the correct answer:** Thyroxine (T3/T4) is unique because, although it is lipid-soluble, its receptors are located **constitutively inside the nucleus** (bound to DNA). Unlike steroid hormones that must translocate from the cytoplasm to the nucleus, thyroid hormone receptors are already present on the thyroid hormone response elements (TRE) of the target genes. Therefore, Thyroxine does **not** act on cytoplasmic receptors. **Analysis of Incorrect Options:** * **Corticosteroids (Glucocorticoids):** These act on **Type 1 Cytoplasmic receptors**. Upon binding, the receptor-ligand complex dissociates from heat shock proteins (hsp90) and translocates into the nucleus. * **Aldosterone (Mineralocorticoids):** Similar to glucocorticoids, aldosterone binds to mineralocorticoid receptors located primarily in the **cytoplasm** of the renal collecting duct cells. * **Vitamin D:** While often grouped with nuclear receptors, the Vitamin D receptor (VDR) is primarily localized in the **cytoplasm** and moves to the nucleus upon activation (though some literature suggests a dual distribution, for NEET-PG purposes, it is categorized with steroids). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Cytoplasmic Receptors:** "**C**an **A**ll **V**itamins **G**o?" (**C**orticosteroids, **A**ldosterone, **V**itamin D, **G**uanylyl cyclase - though the latter is an enzyme). * **Mnemonic for Nuclear Receptors:** "**R**etinoic acid **A**nd **T**hyroid" (**R**etinoic acid, **A**ndrogens/Estrogen/Progesterone*, **T**hyroid). * *Note:* Estrogen and Progesterone receptors are predominantly nuclear, similar to Thyroid hormone. * All intracellular receptors act as **ligand-activated transcription factors**, leading to altered mRNA synthesis and protein expression. This explains their **slow onset of action** (lag period).

Question 7: What is true about tachyphylaxis?

A. Direct sympathomimetic involved
B. Mechanism clearly understood
C. Ephedrine tachyphylaxis reversed with noradrenaline
D. Indirect sympathomimetics involved (Correct Answer)

Explanation: ### Explanation **Tachyphylaxis** is a pharmacological phenomenon characterized by a rapid decrease in response to a drug after repeated administration over a short period. It is a form of "acute tolerance" that cannot be overcome by increasing the dose. **Why Option D is Correct:** Tachyphylaxis is most classically associated with **indirect-acting sympathomimetics** (e.g., **Ephedrine, Tyramine, Amphetamine**). These drugs work by displacing stored norepinephrine (NE) from the presynaptic nerve terminals into the synaptic cleft. With repeated, frequent dosing, the available neuronal stores of NE become depleted faster than they can be replenished. Once the stores are exhausted, the drug loses its efficacy, leading to tachyphylaxis. **Analysis of Incorrect Options:** * **Option A:** Direct sympathomimetics (e.g., Adrenaline, Phenylephrine) act directly on receptors. While they can undergo receptor desensitization (downregulation) over a long period, they do not typically cause the rapid, store-depletion-driven tachyphylaxis seen with indirect agents. * **Option B:** The mechanism is not always "clearly understood" for every drug. While NE depletion explains ephedrine, other drugs (like Nitroglycerin) involve complex oxidative stress or enzyme inactivation mechanisms that are still being researched. * **Option C:** Ephedrine tachyphylaxis is **not** reversed by noradrenaline; rather, the *response* to ephedrine is lost because NE is gone. Administering exogenous NE would restore the physiological effect (vasoconstriction), but it does not "reverse" the exhaustion of the internal stores required for ephedrine to function. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Examples:** Ephedrine (nasal decongestants), Tyramine, Amphetamine, Nicotine, and Nitroglycerin (requires a "drug-free interval" to prevent tolerance). * **Key Distinction:** Unlike **Tolerance** (which develops slowly over weeks), **Tachyphylaxis** develops rapidly (minutes to hours). * **Mechanism:** Most commonly due to **depletion of endogenous mediators** or rapid receptor phosphorylation/internalization.

Question 8: HLA* 1502 is a genetic marker associated with which of the following conditions?

A. Systemic Lupus Erythematosus (SLE)
B. Polyarteritis Nodosa
C. Stevens-Johnson Syndrome (Correct Answer)
D. Seronegative Spondyloarthritis Syndrome

Explanation: ### Explanation **Correct Answer: C. Stevens-Johnson Syndrome** The **HLA-B*1502** allele is a critical pharmacogenetic marker strongly associated with an increased risk of **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)** in patients treated with **Carbamazepine**. This association is particularly prevalent in populations of **East Asian and Southeast Asian** descent (e.g., Han Chinese, Thai, Indians). The mechanism involves a T-cell mediated hypersensitivity reaction where the drug (Carbamazepine) binds to the HLA-B*1502 molecule, triggering an immune response against keratinocytes. Due to this high correlation, the FDA recommends screening for this allele in high-risk populations before initiating Carbamazepine therapy. **Analysis of Incorrect Options:** * **A. Systemic Lupus Erythematosus (SLE):** Associated primarily with **HLA-DR2** and **HLA-DR3**. Drug-induced SLE is linked to "slow acetylators" (NAT2 deficiency) taking drugs like Procainamide or Hydralazine. * **B. Polyarteritis Nodosa:** Strongly associated with **Hepatitis B surface antigen (HBsAg)** positivity, not a specific HLA-B allele. * **D. Seronegative Spondyloarthritis:** This group of disorders (including Ankylosing Spondylitis) is classically associated with **HLA-B27**. **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*5701:** Associated with hypersensitivity to **Abacavir** (NRTI). * **HLA-B*5801:** Associated with SJS/TEN induced by **Allopurinol** (especially in Han Chinese). * **HLA-A*3101:** Another marker for Carbamazepine-induced skin reactions, more common in Europeans and Japanese. * **Drug of choice for SJS/TEN:** Supportive care and IV Immunoglobulins (IVIG). Cyclosporine is also used.

Question 9: Which of the following drugs is hydrolyzed by a plasma esterase that has abnormally low activity in about 1 in every 2500 humans?

A. Ethanol
B. Rifampicin
C. Cimetidine
D. Succinylcholine (Correct Answer)

Explanation: **Explanation:** **1. Correct Option: Succinylcholine** Succinylcholine is a depolarizing neuromuscular blocker used for rapid sequence induction. Its action is normally terminated within 5–10 minutes because it is rapidly hydrolyzed by **Butyrylcholinesterase (BChE)**, also known as **Pseudocholinesterase** or **Plasma Cholinesterase**. About 1 in 2500 individuals (of European descent) carries an autosomal recessive trait for **atypical pseudocholinesterase**. In these patients, the enzyme has a low affinity for the drug, leading to a failure to hydrolyze succinylcholine. This results in prolonged neuromuscular blockade and life-threatening respiratory paralysis, a clinical condition known as **Succinylcholine Apnea**. **2. Incorrect Options:** * **Ethanol:** Primarily metabolized in the liver by Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH). While ALDH deficiency is common in Asian populations (causing "flushing"), it is not a plasma esterase. * **Rifampicin:** A potent inducer of Cytochrome P450 enzymes. It is metabolized via hepatic deacetylation, not plasma esterases. * **Cimetidine:** An H2 blocker and a well-known enzyme inhibitor. It is eliminated via a combination of hepatic metabolism and renal excretion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dibucaine Number:** This is the diagnostic test for atypical pseudocholinesterase. Dibucaine inhibits normal enzyme by 80%, but atypical enzyme by only 20%. A **low Dibucaine number** indicates a high risk for apnea. * **Management:** If apnea occurs, the patient must be maintained on **mechanical ventilation** until the drug wears off naturally. * **Mivacurium:** Another neuromuscular blocker also metabolized by pseudocholinesterase that can cause prolonged paralysis in these patients.

Question 10: Which statement related to the expiry date of a drug is true?

A. It is the date up to which the drug is likely to be fully potent and safe to take based on scientifically-sound product testing, if stored properly. (Correct Answer)
B. The maximum period of expiry is 3 years from the date of manufacture.
C. After the expiry period, there is a fall in the efficacy of the drug.
D. After the expiry period, the drug changes to more toxic compounds.

Explanation: **Explanation** The expiry date of a drug is a strictly regulated parameter determined by stability testing. **1. Why Option A is correct:** The expiry date represents the final day that the manufacturer guarantees the **full potency and safety** of a drug. This is based on real-time and accelerated stability studies. For a drug to be considered "within expiry," it must typically retain at least **90% of its labeled potency** and remain free from significant toxic degradation, provided it has been stored under the specific conditions (temperature, light, humidity) mentioned on the label. **2. Why the other options are incorrect:** * **Option B:** There is no universal "3-year" rule. The shelf life varies significantly depending on the chemical stability of the active pharmaceutical ingredient (API). Some drugs expire in 6 months, while others are stable for 5 years. * **Option C:** While efficacy *does* decrease over time, this is not the definition of the expiry date itself. Furthermore, many drugs remain 100% effective for a period after the date; the expiry is simply the legal limit of the manufacturer's guarantee. * **Option D:** While some drugs (like Tetracyclines) can degrade into toxic metabolites (e.g., causing Fanconi syndrome), this is the **exception, not the rule**. Most drugs simply lose potency rather than becoming acutely toxic. **High-Yield Clinical Pearls for NEET-PG:** * **The SLEP (Shelf Life Extension Program):** Studies by the FDA have shown many stockpiled drugs remain potent for years past their expiry, but for clinical practice, the labeled date is the legal standard. * **Tetracycline Warning:** Expired tetracycline is classically associated with **Fanconi Syndrome** (proximal renal tubular acidosis). * **Storage Matters:** Potency loss is accelerated by "vial-to-vial" variability and improper storage (e.g., leaving nitroglycerin in sunlight).

Practice by Chapter

Genetic Basis of Drug Response

Practice Questions

Pharmacogenomic Testing

Practice Questions

Cytochrome P450 Polymorphisms

Practice Questions

Pharmacogenomics of Drug Transporters

Practice Questions

Pharmacogenomics in Oncology

Practice Questions

Pharmacogenomics in Cardiovascular Therapeutics

Practice Questions

Pharmacogenomics in Psychiatry

Practice Questions

Personalized Medicine Approaches

Practice Questions

Ethical Considerations in Pharmacogenomics

Practice Questions

Implementation of Pharmacogenomics in Clinical Practice

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free